Nifty 50 ka rebound: In technical charts par rakhein nazar, kya ye stocks bhagenge?

BROKERAGE-REPORTS
Whalesbook Logo
AuthorIshaan Verma|Published at:
Nifty 50 ka rebound: In technical charts par rakhein nazar, kya ye stocks bhagenge?

Market ab stabilize ho raha hai, aur analysts ne kuch stocks identify kiye hain jahan technical patterns potential trend reversal ki taraf ishara kar rahe hain. Nifty 50 ke sambhalne ke baad ab in stocks par focus badh gaya hai.

Nifty 50 mein aaye recent volatility ke baad, ab market experts wapas chart patterns par focus kar rahe hain. Traders ab Deepak Fertilisers, HDFC Life aur Sun Pharma jaise stocks ko closely monitor kar rahe hain taaki momentum shift ko catch kiya ja sake. Technical analysis ka simple matlab hai—historical data aur price movement ko dekh kar future trend ka andaza lagana.

Kya chal raha hai technicals mein?

Analysts aaj kal Fibonacci retracements aur RSI (Relative Strength Index) ka use kar rahe hain taaki ye pata chale ki kaunsa stock oversold hai ya kahan support mil sakta hai. Pharma sector mein Sun Pharmaceutical aur Lupin ke charts dekh kar lag raha hai ki shayad unka correction phase khatam ho gaya hai. Wahi, financial segment mein HDFC Life Insurance aur Muthoot Finance apne base bana rahe hain.

Sector-wise kya update hai?

Consumer aur industrial sector bhi peeche nahi hain. Jubilant Foodworks aur Sapphire Foods mein strength dikh rahi hai, jabki Deepak Fertilisers aur Samvardhana Motherson ko unke support levels par track kiya ja raha hai. ITC ke futures data par bhi traders ki gehri nazar hai, khaas karke monthly expiry ke nazdeek.

Risk ko ignore mat karna

Ek baat yaad rakhein, technical indicators hamesha sahi nahi hote. Sudden market correction ya global news kabhi bhi in setups ko invalidate kar sakti hai. RSI divergence ya trendline breakout sirf ek tool hai, pura bharosa isi par mat karna. Hamesha fundamental analysis (earnings aur business health) ko sath lekar chalein, tabhi trade lene ka sahi risk-to-reward ratio milega.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.